Department of Clinical Medicine

You are here: » Jesper Møller Jensen » Research outputs » CAD Severity on Cardiac CTA Identifies Patients With Most...

Jesper Møller Jensen

CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Standard

CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets. / Mortensen, Martin Bødtker; Steffensen, Flemming Hald; Bøtker, Hans Erik et al.
In: J A C C: Cardiovascular Imaging, Vol. 13, No. 9, 09.2020, p. 1961-1972.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Harvard

Mortensen, MB, Steffensen, FH, Bøtker, HE, Jensen, JM, Rønnow Sand, NP, Kragholm, KH, Kanstrup, H, Sørensen, HT, Leipsic, J, Blaha, MJ & Nørgaard, BL 2020, 'CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets', J A C C: Cardiovascular Imaging, vol. 13, no. 9, pp. 1961-1972. https://doi.org/10.1016/j.jcmg.2020.03.017

APA

Mortensen, M. B., Steffensen, F. H., Bøtker, H. E., Jensen, J. M., Rønnow Sand, N. P., Kragholm, K. H., Kanstrup, H., Sørensen, H. T., Leipsic, J., Blaha, M. J., & Nørgaard, B. L. (2020). CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets. J A C C: Cardiovascular Imaging, 13(9), 1961-1972. https://doi.org/10.1016/j.jcmg.2020.03.017

CBE

Mortensen MB, Steffensen FH, Bøtker HE, Jensen JM, Rønnow Sand NP, Kragholm KH, Kanstrup H, Sørensen HT, Leipsic J, Blaha MJ, et al. 2020. CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets. J A C C: Cardiovascular Imaging. 13(9):1961-1972. https://doi.org/10.1016/j.jcmg.2020.03.017

MLA

Mortensen, Martin Bødtker et al. "CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets". J A C C: Cardiovascular Imaging. 2020, 13(9). 1961-1972. https://doi.org/10.1016/j.jcmg.2020.03.017

Vancouver

Mortensen MB, Steffensen FH, Bøtker HE, Jensen JM, Rønnow Sand NP, Kragholm KH et al. CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets. J A C C: Cardiovascular Imaging. 2020 Sept;13(9):1961-1972. Epub 2020 Jun 17. doi: 10.1016/j.jcmg.2020.03.017

Author

Mortensen, Martin Bødtker ; Steffensen, Flemming Hald ; Bøtker, Hans Erik et al. / CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets. In: J A C C: Cardiovascular Imaging. 2020 ; Vol. 13, No. 9. pp. 1961-1972.

Bibtex

@article{87669013fd664c64a03473d63e0ecb0d,
title = "CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets",
abstract = "OBJECTIVES: This study aimed to assess if information on CAD severity from coronary computed tomography angiography (CTA) can identify patients that benefit most from treating low-density lipoprotein-cholesterol (LDL-C) to American Heart Association/American College of Cardiology (ACC/AHA) and European Society of Cardiology (ESC) guidelines targets.BACKGROUND: Current treatment guidelines for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) disregard severity of coronary artery disease (CAD) for treatment choices. It is unclear whether severity of CAD should be considered in treatment recommendations.METHODS: Among 20,241 symptomatic patients undergoing diagnostic CTA from the Western Denmark Heart Registry, we assessed the number needed to treat (NNT) in 6 years to prevent 1 ASCVD event as well as the proportion of all events that could be prevented by treating LDL-C to targets. We assumed a 22% relative reduction of ASCVD events per 1 mmol/l reduction in LDL-C.RESULTS: In multivariable analysis with no CAD as the reference, the subdistribution hazard ratio for ASCVD events was 4.0 (95% confidence interval [CI]: 3.3 to 4.9) for 1-vessel disease, 4.6 (3.5 to 6.0) for 2-vessel disease, and 5.6 (4.0 to 8.0) for 3-vessel disease. Consequently, the NNT to prevent 1 ASCVD event in 6 years by treating LDL-C to targets varied greatly from 233 (ESC) and 110 (ACC/AHA) for patients with no CAD to 8-9 for patients with 3-vessel disease (both ACC/AHA and ESC). The estimated percentage of ASCVD events that could be prevented by achieving guideline targets was 30% to 36% for patients with obstructive disease. However, <20% of patients achieved targets.CONCLUSIONS: An individualized approach based on CAD severity can identify symptomatic patients that are likely to derive most and least benefit from treating LDL-C to ACC/AHA and ESC treatment targets.",
author = "Mortensen, {Martin B{\o}dtker} and Steffensen, {Flemming Hald} and B{\o}tker, {Hans Erik} and Jensen, {Jesper M{\o}ller} and {R{\o}nnow Sand}, {Niels Peter} and Kragholm, {Kristian Hay} and Helle Kanstrup and S{\o}rensen, {Henrik Toft} and Jonathon Leipsic and Blaha, {Michael J} and N{\o}rgaard, {Bjarne Linde}",
note = "Copyright {\textcopyright} 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = sep,
doi = "10.1016/j.jcmg.2020.03.017",
language = "English",
volume = "13",
pages = "1961--1972",
journal = "J A C C: Cardiovascular Imaging",
issn = "1936-878X",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL Cholesterol to ACC/AHA and ESC/EAS Targets

AU - Mortensen, Martin Bødtker

AU - Steffensen, Flemming Hald

AU - Bøtker, Hans Erik

AU - Jensen, Jesper Møller

AU - Rønnow Sand, Niels Peter

AU - Kragholm, Kristian Hay

AU - Kanstrup, Helle

AU - Sørensen, Henrik Toft

AU - Leipsic, Jonathon

AU - Blaha, Michael J

AU - Nørgaard, Bjarne Linde

N1 - Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2020/9

Y1 - 2020/9

N2 - OBJECTIVES: This study aimed to assess if information on CAD severity from coronary computed tomography angiography (CTA) can identify patients that benefit most from treating low-density lipoprotein-cholesterol (LDL-C) to American Heart Association/American College of Cardiology (ACC/AHA) and European Society of Cardiology (ESC) guidelines targets.BACKGROUND: Current treatment guidelines for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) disregard severity of coronary artery disease (CAD) for treatment choices. It is unclear whether severity of CAD should be considered in treatment recommendations.METHODS: Among 20,241 symptomatic patients undergoing diagnostic CTA from the Western Denmark Heart Registry, we assessed the number needed to treat (NNT) in 6 years to prevent 1 ASCVD event as well as the proportion of all events that could be prevented by treating LDL-C to targets. We assumed a 22% relative reduction of ASCVD events per 1 mmol/l reduction in LDL-C.RESULTS: In multivariable analysis with no CAD as the reference, the subdistribution hazard ratio for ASCVD events was 4.0 (95% confidence interval [CI]: 3.3 to 4.9) for 1-vessel disease, 4.6 (3.5 to 6.0) for 2-vessel disease, and 5.6 (4.0 to 8.0) for 3-vessel disease. Consequently, the NNT to prevent 1 ASCVD event in 6 years by treating LDL-C to targets varied greatly from 233 (ESC) and 110 (ACC/AHA) for patients with no CAD to 8-9 for patients with 3-vessel disease (both ACC/AHA and ESC). The estimated percentage of ASCVD events that could be prevented by achieving guideline targets was 30% to 36% for patients with obstructive disease. However, <20% of patients achieved targets.CONCLUSIONS: An individualized approach based on CAD severity can identify symptomatic patients that are likely to derive most and least benefit from treating LDL-C to ACC/AHA and ESC treatment targets.

AB - OBJECTIVES: This study aimed to assess if information on CAD severity from coronary computed tomography angiography (CTA) can identify patients that benefit most from treating low-density lipoprotein-cholesterol (LDL-C) to American Heart Association/American College of Cardiology (ACC/AHA) and European Society of Cardiology (ESC) guidelines targets.BACKGROUND: Current treatment guidelines for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) disregard severity of coronary artery disease (CAD) for treatment choices. It is unclear whether severity of CAD should be considered in treatment recommendations.METHODS: Among 20,241 symptomatic patients undergoing diagnostic CTA from the Western Denmark Heart Registry, we assessed the number needed to treat (NNT) in 6 years to prevent 1 ASCVD event as well as the proportion of all events that could be prevented by treating LDL-C to targets. We assumed a 22% relative reduction of ASCVD events per 1 mmol/l reduction in LDL-C.RESULTS: In multivariable analysis with no CAD as the reference, the subdistribution hazard ratio for ASCVD events was 4.0 (95% confidence interval [CI]: 3.3 to 4.9) for 1-vessel disease, 4.6 (3.5 to 6.0) for 2-vessel disease, and 5.6 (4.0 to 8.0) for 3-vessel disease. Consequently, the NNT to prevent 1 ASCVD event in 6 years by treating LDL-C to targets varied greatly from 233 (ESC) and 110 (ACC/AHA) for patients with no CAD to 8-9 for patients with 3-vessel disease (both ACC/AHA and ESC). The estimated percentage of ASCVD events that could be prevented by achieving guideline targets was 30% to 36% for patients with obstructive disease. However, <20% of patients achieved targets.CONCLUSIONS: An individualized approach based on CAD severity can identify symptomatic patients that are likely to derive most and least benefit from treating LDL-C to ACC/AHA and ESC treatment targets.

U2 - 10.1016/j.jcmg.2020.03.017

DO - 10.1016/j.jcmg.2020.03.017

M3 - Journal article

C2 - 32563656

VL - 13

SP - 1961

EP - 1972

JO - J A C C: Cardiovascular Imaging

JF - J A C C: Cardiovascular Imaging

SN - 1936-878X

IS - 9

ER -